Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
24-26 June, 2025
Not Confirmed
Not Confirmed
09-11 June, 2025
Annual Outsourcing in ...Annual Outsourcing in CT
Not Confirmed
Not Confirmed
10-11 June, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 June, 2025
Industry Trade Show
Not Confirmed
09-11 June, 2025
Annual Outsourcing in ...Annual Outsourcing in CT
Industry Trade Show
Not Confirmed
10-11 June, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-announces-restructuring-post-iff-pharma-buyout-who-fda-advance-regulatory-frameworks
16 Apr 2025
// INDPHARMAPOST
https://www.indianpharmapost.com/news/rising-pharma-gets-final-approval-from-usfda-for-mesalamine-suppositories-1000-mg-17029
26 Mar 2025
// FDA
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-march-26-2025-60230.pdf
15 Jan 2025
// FDA
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-january-15-2025-7287.pdf
13 Sep 2024
// BUSINESSWIRE
07 Jun 2024
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218283
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217412
Details:
Mesalamine is a small molecule drug, prostaglandin and leukotriene inhibitor, indicated for the treatment of ulcerative proctitis.
Lead Product(s): Mesalazine
Therapeutic Area: Immunology Brand Name: Mesalamine-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 16, 2025
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Rising Pharma gets final approval from USFDA for Mesalamine Suppositories 1000 mg
Details : Mesalamine is a small molecule drug, prostaglandin and leukotriene inhibitor, indicated for the treatment of ulcerative proctitis.
Product Name : Mesalamine-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 16, 2025
ABOUT THIS PAGE